



This Patient Group Direction (PGD) must only be used by registered healthcare professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

PATIENT GROUP DIRECTION (PGD)

Supply of ulipristal acetate 30mg tablet for emergency contraception

**For use by authorised community pharmacists working in a
pharmacy which is contracted by Hertfordshire County Council to
provide the service**

Version Number 1.0

Reference number Ulipristal PGD HCC202402v1.0

Change History	
Version	Change details
Version 1	<ul style="list-style-type: none"> • New template adopted from Specialist Pharmacy Services (SPS) by HCC with local changes
Version 1a	<ul style="list-style-type: none"> • Appendix A (Registered Pharmacist Authorisation Sheet) amended so that a senior person with designated authority within the provider organisation can sign as authorising manager.
Version 2.0	<ul style="list-style-type: none"> • Template updated to match layout and formatting of other HCC PGDs • Inclusion and Exclusion details updated • Breastfeeding details updated • Drug interactions detailed • Updated email and contact details • Appendix B - Children Safeguarding pathway updated • Appendix C and D added (signposting and decision making)

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

Version 3.0	<ul style="list-style-type: none">• Upper age restriction caps removed• Appendix C and D updated to include information about out of hours advice• Acute porphyria added to exclusions• Updated detail in exclusion and cautions in relation to oral contraceptives in line with current FSRH guidance• Training requirements updated• Administration removed from title• PGD reference number updated• PGD validity dates updated• Working group names updated
-------------	---

This Patient Group Direction (PGD) must only be used by registered professionals who have been named and authorised by their organisation to practise under it (See Appendix A). The most recent and in date final signed version of the PGD must be used.

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026




Expiry date: 31/03/2027

Date PGD template comes into effect:	01/04/2024
Review date	01/10/2026
Expiry date:	31/03/2027

PGD HERTFORDSHIRE DEVELOPMENT GROUP

This PGD template has been based on the national template approved by BASHH and has been peer reviewed by the Hertfordshire PGD working group as named below.

ORGANISATIONAL AUTHORISATIONS

Name	Job title and organisation	Signature	Date
Senior Doctor	Dr Anna Mallott		02-Apr-2024
Senior Pharmacist	Rebecca Thomas		02-Apr-2024
Chair of Hertfordshire Public Health Quality and Assurance Governance Group	David Conrad Consultant in Public Health Evidence and Improvement. Chair of Hertfordshire Public Health Quality and Assurance Governance Group		02-Apr-2024

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

PGD DEVELOPMENT

Hertfordshire Sexual Health PGD Review Group 2020 - Version 1	
Senior Doctor:	Dr. Linda Mercy
Senior Pharmacist:	Dipti Patel
Representative of professional group using the PGD:	Helen Musson
Community Pharmacist:	Purvi Barchha
Chair of the PH AGG (Public Health Consultant):	David Conrad
Lead Nurse- Sexual Health Herts:	Gillian Miles
Health Improvement Lead- Sexual Health:	Rob Bacon

Hertfordshire Sexual Health PGD Review Group 2022 - Version 2	
Senior Doctor:	Dr. Joel Bonnet
Senior Pharmacist:	Rebecca Thomas
Representative of professional group using the PGD:	Farhan Moulana
Lead Nurse- Sexual Health Herts:	Lorraine Deane
Health Improvement Lead- Sexual Health:	Rob Bacon
Health Improvement Lead – Health Care Partnerships	Hayley Golding
Commissioning Officer:	Helen Cleary

Hertfordshire Sexual Health PGD Review Group 2022 - Version 3	
Senior Doctor:	Dr. Anna Mallott
Senior Pharmacist:	Rebecca Thomas
Representative of professional group using the PGD:	Farhan Moulana
Lead Nurse- Sexual Health Herts:	Lorraine Deane
Health Improvement Lead- Sexual Health:	Rob Bacon
Health Improvement Lead – Health Care Partnerships	Ruth Dean
Commissioning Officer:	Eleanor Gage

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

1. Characteristics of staff

Qualifications and professional registration	<ul style="list-style-type: none"> Registered Pharmacist working in premises that hold a public health contract with Hertfordshire County Council.
Initial training	<ul style="list-style-type: none"> The Registered Pharmacist authorised to operate under this PGD must have undertaken appropriate education and training and successfully demonstrated the competencies to undertake clinical assessment of client to safely provide medicines listed in accordance with local policy. To deliver this service, the pharmacist should have evidence of competence in the clinical skills and knowledge covered in the following training modules on the Centre for Pharmacy Postgraduate Education (CPPE): <ol style="list-style-type: none"> CPPE Emergency contraception: (https://www.cppe.ac.uk/gateway/ehc) CPPE Consultation Skills - Face to face and remote (https://www.cppe.ac.uk/gateway/cs-ftfr) CPPE Sexual health in pharmacies (https://www.cppe.ac.uk/programmes/l/sexual-e-01) Pharmacists providing the service will be personally responsible for remaining up to date with the skills and competencies. Before commencement of the service, the pharmacy contractor must ensure that pharmacists and pharmacy staff providing the service are competent to do so and are familiar with the sexual health services offered and how to refer to other services when required. This may involve completion of training. Pharmacists are recommended to successfully complete relevant contraception module/course accredited or endorsed by the FSRH, CPPE or a university or advised in the RCN training directory. The Pharmacist must have completed required training (including updates) in safeguarding children and vulnerable adults or level 2 safeguarding or the equivalent.

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

Competency assessment	<ul style="list-style-type: none"> Pharmacists operating under this PGD must be assessed as competent (see Appendix A) https://www.cppe.ac.uk/programmes/l/ehc-e-03/). Pharmacists operating under this PGD are encouraged to review their competency using the NICE Competency Framework for health professionals using patient group directions.
Ongoing training and competency	<ul style="list-style-type: none"> Pharmacists operating under this PGD are personally responsible for ensuring that they remain up to date with the use of all medicines and guidance included in the PGD - if any training needs are identified these should be addressed and further training completed as necessary. Organisational PGD and/or medication training completed as required by employing organisation.
Additional requirements	<ul style="list-style-type: none"> The Pharmacist must obtain a satisfactory Disclosure & Barring Check (DBS) with Adult & Child Workforce checks. The DBS can be obtained via the pharmacist's employer, an independent provider or Hertfordshire County Council. The DBS should be renewed every 3 years. Community Pharmacy Hertfordshire (Herts LPC) and Hertfordshire County Council strongly encourage Pharmacists that have received the updated DBS check from HCC, to then register for the update service online (https://www.gov.uk/dbs-update-service). Has completed appropriate training for working under PGDs for supply and administration of medicines. Competence in the assessment of clients using Fraser competency guidelines. Is up to date with training and updating in safeguarding children and vulnerable adults. Knowledge of Child Protection Guidelines/ safeguarding for Hertfordshire and how to escalate any concerns (Appendix B). User of PGD is required to follow the flow charts detailed in Appendix C and D.
<p>The decision to supply medication rests with the individual registered health professional who must abide by the PGD and any associated organisational policies.</p>	

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

2. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	<p>To reduce the risk of pregnancy after unprotected sexual intercourse (UPSI) or regular non-hormonal contraception has been compromised or used incorrectly.</p>
Criteria for inclusion	<ul style="list-style-type: none"> • Females aged over 13 years who are deemed to be Fraser competent and presenting for emergency contraception (EC) between 0 and 120 hours following UPSI or when regular contraception has been compromised or used incorrectly. • No contraindications to the medication. • Informed consent given. • Must be present - In the event of services being restricted and face-to-face consultations unavailable or patients choosing this option, pharmacists can offer EHC telephone or video consultation in accordance with NHSE guidance. Children under 16 years of age should still be offered face-to-face consultations and that clear pathways are in place to signpost them appropriately.
Criteria for exclusion	<ul style="list-style-type: none"> • Under 13 years of age. • Clients under the age of 13 must be signposted to attend Sexual Health Hertfordshire or A&E (if out of hours) and a referral to the safeguarding team must be completed (follow Appendix B) • Informed consent not given. • Not present in person - note: see above inclusions • Knowingly supplying to a third party. • Undiagnosed vaginal bleeding. • Clients under 16 years old and assessed as lacking capacity to consent using the Fraser Guidelines. • Clients 16 years of age and over and assessed as lacking capacity to consent. • This episode of UPSI occurred more than 120 hours ago. N.B. A dose may be given if there have been previous untreated or treated episodes of UPSI within the current cycle if the most recent episode of UPSI is within 120 hours. • Known or suspected pregnancy (N.B. a previous episode of UPSI in this cycle is not an exclusion. Consider pregnancy test if more than three weeks after UPSI and no normal menstrual period).

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	<ul style="list-style-type: none"> • Less than 21 days after childbirth. • Less than 5 days after miscarriage, abortion, ectopic pregnancy or uterine evacuation for gestational trophoblastic disease (GTD). • Known hypersensitivity to the active ingredient or to any component of the product - see Summary of Product Characteristics. • Use of levonorgestrel or any other progestogen in the previous 7 days (i.e. hormonal contraception, including combined oral contraception, hormone replacement therapy or use for other gynaecological indications). • Breast cancer, cervical cancer, ovarian cancer or uterine cancer. • Severe asthma controlled by oral glucocorticoids. • Clients using enzyme-inducing drugs/herbal products or within 4 weeks of stopping (see drug interactions section). • Acute Porphyria.
<p>Cautions including any relevant action to be taken</p>	<ul style="list-style-type: none"> • All clients should be informed that insertion of a copper intrauterine device (Cu-IUD) within five days of UPSI or within five days from earliest estimated ovulation is the most effective method of emergency contraception. If a Cu-IUD is appropriate and acceptable supply oral EC and refer to the appropriate health service provider. • Ulipristal is ineffective if taken after ovulation. • If the client vomits within three hours from ingestion, a repeat dose may be given. • Body Mass Index (BMI) >26kg/m² or weight >70kg – client should be advised that though oral EC methods may be safely used, a high BMI may reduce the effectiveness. A Cu-IUD should be recommended as the most effective method of EC. • Consideration should be given to the current disease status of those with severe malabsorption syndromes, such as acute/active inflammatory bowel disease or Crohn’s disease. Although the use of ulipristal is not contra-indicated it may be less effective and so these clients should be advised that insertion of Cu-IUD would be the most effective emergency contraception for them and referred accordingly if agreed. • Breast feeding – Ulipristal is not the preferred emergency contraceptive during breastfeeding. The FSRH recommends discarding breast milk for 7 days after taking ulipristal. • The effectiveness of ulipristal can be reduced by progestogen taken in the following 5 days and clients must be advised not to take progestogen-containing drugs including combined oral contraception for 5 days after ulipristal. Ulipristal is generally not recommended in a

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	<p>missed pill situation. See section ‘Written information and further advice to be given to client’.</p> <ul style="list-style-type: none"> • If the client is less than 16 years of age an assessment based on Fraser guidelines must be made and documented. • If the client is less than 13 years of age the pharmacist must speak to local safeguarding lead and follow the local safeguarding policy (Appendix B). • If you have concerns regarding an adult who is being abused or neglected, call 0300 123 4042 (open 24 hours a day). For more information visit: https://www.hertfordshire.gov.uk/services/adult-social-services/report-a-concern-about-an-adult/professionals-request-social-care/professionals-make-an-social-care-referral.aspx • If the client has not yet reached menarche consider immediate onward referral for further assessment or investigation to their GP or Sexual Health Hertfordshire Service (SHH) call 0300 008 5522.
<p>Action to be taken if the individual is excluded or declines treatment</p>	<ul style="list-style-type: none"> • If declined ensure client is aware of the need for treatment and the potential consequences of not receiving treatment. • Explain the reasons for exclusion to the client and document in the consultation record. • Record reason for decline in the consultation record. • Offer suitable alternative emergency contraception or refer the client as soon as possible to a Sexual Health Hertfordshire clinic: https://www.sexualhealthhertfordshire.clch.nhs.uk/ or GP if appropriate and/or provide them with information about further options. • If EHC is unable to be provided, Pharmacists should signpost clients to an alternative service - see Appendix D. • Client should be advised of the risk of pregnancy and advised to test for pregnancy via a home test kit or to visit their GP or Sexual Health Hertfordshire Service (SHH) call 0300 008 5522.
<p>Additional guidance for client under 16 years of age</p>	<ul style="list-style-type: none"> • Pharmacists will have the same duty of care regardless of client’s age. • Pharmacist is able to provide contraceptive, sexual, and reproductive health advice and treatment, without parental knowledge or consent, to clients over 13 years and under 16 years, provided that: <ul style="list-style-type: none"> ○ Client understands the advice provided and its implications. ○ The client may be advised to talk to their parents, but must not be persuaded to tell their parents, or persuaded to allow the pharmacist to tell their parents that they are seeking contraceptive advice. ○ The client is likely to begin or continue having unprotected sex with or without contraceptive treatment. ○ Her physical or mental health would otherwise be likely to suffer and so provision of advice or treatment is in their best interest.

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	<ul style="list-style-type: none"> • Health professionals who do not offer contraceptive services to under 16s should ensure that alternative arrangements are in place for them to be seen urgently elsewhere. • All services providing contraceptive advice and treatment to young people should have a confidentiality policy making clear that under 16s have the same right to confidentiality as an adult considering Fraser guidelines and safeguarding.
--	---

3. Description of treatment

Name, strength & formulation of drug	Ulipristal acetate 30mg tablet
Legal category	P/ POM
Route of administration	Oral
Off label use	<p>This guidance on off label use is based on the best practice given by Faculty of Sexual and Reproductive Healthcare (FSRH) and may vary from the Summary of Product Characteristics (SPC) or British National Formulary https://bnf.nice.org.uk/drugs/ulipristal-acetate/</p> <p>This PGD includes off-label use in the following conditions:</p> <ul style="list-style-type: none"> • Lapp-lactase deficiency • Hereditary problems of galactose intolerance • Glucose-galactose malabsorption • Severe hepatic impairment <p>Drugs should be stored according to the conditions detailed in the Storage section in this table. However, in the event of an inadvertent or unavoidable deviation of these conditions the local pharmacy or Medicines Management team must be consulted.</p> <p>Where drugs have been assessed by pharmacy/Medicines Management in accordance with national or specific product recommendations as appropriate for continued use this would constitute off-label administration under this PGD. The responsibility for the decision to release the affected drugs for use lies with pharmacy/Medicines Management.</p> <p>Where a drug is recommended off-label consider, as part of the consent process, informing the client/parent/carer that the drug is being offered in accordance with national guidance but that this is outside the product</p>

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	licence.
Dose and frequency of administration	<ul style="list-style-type: none"> One ulipristal acetate tablet (30mg) as a single dose taken as soon as possible up to 120 hours after UPSI.
Duration of treatment	<ul style="list-style-type: none"> A single dose is permitted under this PGD. If vomiting occurs within 3 hours of ulipristal being taken a repeat dose can be supplied under this PGD. Repeated doses can be given within the same cycle. Please note: <ul style="list-style-type: none"> If within 7 days of previous levonorgestrel offer levonorgestrel again (not ulipristal) If within 5 days of ulipristal then offer ulipristal again (not levonorgestrel)
Quantity to be supplied	Appropriately labelled pack of one tablet.
Storage	Medicines must be stored securely according to national guidelines and in accordance with the product SPC.
Drug interactions	<p>All concurrent medication should be reviewed for interactions. Medicines listed below are classed in the BNF as causing severe drug interactions with ulipristal.</p> <p>Additional information for drug interactions can be found: https://www.fsrh.org/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/</p> <p>Ulipristal metabolism is enhanced by concomitant use of liver enzyme inducers or use of such is the previous 28 days. These medicines can reduce the effect of ulipristal, these drugs include:</p> <ul style="list-style-type: none"> Anticonvulsants: Phenobarbital, primidone, carbamazepine, eslicarbazepine, phenytoin, fosphenytoin, oxcarbazepine, topiramate, perampanel, rufinamide. Antifungal: Griseofulvin. Rifamycins: Rifabutin, rifampicin. Herbal medicine: St Johns Wort. Some HIV medicines including: Ritonavir, efavirenz, nevirapine. Endothelin receptor antagonist: Bosentan. Mucolytic: Lumacaftor. Neurokinin receptor antagonists: Aprepitant, fosaprepitant. Centrally acting sympathomimetic: Modafinil. Anti-androgens: Apalutamide, enzalutamide Protein kinase inhibitors: Dabrafenib Progestogens: Desogestrel, etonogestrel, levonorgestrel, norethisterone Antineoplastics (other): Mitotane Hormonal contraception, hormone replacement therapy or use for other gynaecological indications): Use of levonorgestrel or any other progestogen in the previous 7 days may reduce the efficacy of hormonal

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	<p>contraceptives which has implications for on-going contraception.</p> <ul style="list-style-type: none"> • Products that increase gastric pH such as proton pump inhibitors or antacids may reduce plasma concentrations of ulipristal and may decrease efficacy of EHC. <p>A number of drugs are predicted to increase the exposure to ulipristal. These medicines include:</p> <ul style="list-style-type: none"> • Protease inhibitors: Atazanavir, darunavir, lopinavir, tipranavir, fosamprenavir • Pharmacokinetic enhancers: Cobicistat • Protein kinase inhibitors: Idelalisib • Triazole antifungals: Itraconazole, ketoconazole, voriconazole • Macrolide: Clarithromycin. <p>A detailed list of drug interactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk or the BNF www.bnf.org</p>
<p>Identification & management of adverse reactions</p>	<p>A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk and BNF www.bnf.org.</p> <p>The following side effects are common with ulipristal acetate (but may not reflect all reported side effects):</p> <ul style="list-style-type: none"> • Asthenia • breast abnormalities • dizziness • endometrial thickening • gastrointestinal discomfort • headaches • hot flush • menstrual cycle irregularities • mood altered • myalgia • nausea • ovarian and fallopian tube disorders • pain • pelvic pain • skin reactions • vertigo • vomiting

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	<ul style="list-style-type: none"> • weight increased • The FSRH advises that disruption to the menstrual cycle is possible following emergency contraception.
Management of and reporting procedure for adverse reactions	<ul style="list-style-type: none"> • Healthcare professionals and clients/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: http://yellowcard.mhra.gov.uk • Record all adverse drug reactions (ADRs) in the client's medical record. • Report any adverse reactions via organisation incident policy. • Report to Hertfordshire County Council via PHcommissioning@hertfordshire.gov.uk.
Written information and further advice to be given to individual	<ul style="list-style-type: none"> • All methods of emergency contraception should be discussed. All clients should be informed that fitting a Cu-IUD within five days of UPSI or within five days from the earliest estimated ovulation is the most effective method of emergency contraception. • Ensure that a patient information leaflet (PIL) is provided within the original pack. • If vomiting occurs within three hours of taking the dose, the client should return for another dose. • Explain that menstrual disturbances can occur after the use of emergency hormonal contraception. <p>Provide advice on ongoing contraceptive methods, including how these can be accessed. Online information can be accessed from https://www.sexualhealthhertfordshire.clch.nhs.uk/</p> <ul style="list-style-type: none"> • Repeated episodes of UPSI within one menstrual cycle - the dose may be repeated more than once in the same menstrual cycle should the need occur. • In line with FSRH guidance client using hormonal contraception should delay restarting their regular hormonal contraception for 5 days following ulipristal acetate use. Avoidance of pregnancy risk (i.e. use of condoms or abstain from intercourse) should be advised until fully effective. • Advise a pregnancy test three weeks after treatment especially if the expected period is delayed by more than seven days or abnormal (e.g. shorter or lighter than usual), or if using hormonal contraception, which may affect bleeding pattern. • Promote the use of condoms to protect against sexually transmitted

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	<p>infections (STIs) and advise on the possible need for screening for STIs.</p> <ul style="list-style-type: none"> • There is no evidence of harm if someone becomes pregnant in a cycle when they had used emergency hormonal contraception.
Advice / follow up treatment	<ul style="list-style-type: none"> • The client should be advised to seek medical advice in the event of an adverse reaction. • The client should attend an appropriate health service provider if their period is delayed, absent or abnormal or if they are otherwise concerned. • Pregnancy test as required (see advice to client above). • Client advised how to access on-going contraception and STI screening as required. For more information visit https://www.sexualhealthertfordshire.clch.nhs.uk/
Records	<ul style="list-style-type: none"> • Records should be signed and dated (or a password-controlled e-record) and securely kept for a defined period in line with local policy. • All records should be clear, legible and contemporaneous • A record of all client receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy. • The Public Health Designated Database (currently PharmOutcomes) should be used in the first instance, if not readily available then the pharmacy is able to use paper proformas. • The paper copy should be kept in the pharmacy according to the record keeping procedures. The details should be added on to PharmOutcomes as soon as possible and then the paper copy shredded immediately and treated as confidential waste. • The PharmOutcomes record will act as the record retained by the Pharmacy for 8 years (adults) or until the 25th birthday in a child (age 26 if entry made when the person was 17). <p>In discussion with the client enter treatment details onto PharmOutcomes to ensure payment within 10 days of the consultation date.</p> <p>Record:</p> <ul style="list-style-type: none"> • The consent of the client and <ul style="list-style-type: none"> ○ If client is under 13 years of age record action taken ○ If client is under 16 years of age document capacity using Fraser

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

	<p>guidelines. If they are not competent - record the action taken. If client is over 16 years of age and not competent, record action taken</p> <ul style="list-style-type: none">• Name of client, postcode, date of birth• GP contact details where appropriate• Relevant past and present medical history, including medication history. Examination finding where relevant e.g. weight• Any known drug allergies• Name of registered health professional operating under the PGD• Name of medication supplied• Date of supply• Dose supplied• Quantity supplied including batch and expiry date• Advice given, including advice given if excluded or declines treatment• Details of any adverse drug reactions and actions taken• Advice given about the medication including side effects, benefits, and when and what to do if any concerns• Any referral arrangements made• Any supply outside the terms of the product marketing authorisation• Record that supplied via Patient Group Direction (PGD).
--	--

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

4. Key references

Key references (accessed March 2024)	<ul style="list-style-type: none"> • Electronic Medicines Compendium http://www.medicines.org.uk/ • Electronic BNF https://bnf.nice.org.uk/ • NICE Medicines practice guideline “Patient Group Directions” https://www.nice.org.uk/guidance/mpg2 • Faculty of Sexual and Reproductive Health Clinical Guidance: Emergency Contraception – March 2017, amended July 2023 https://www.fsrh.org/standards-and-guidance/current-clinical-guidance/emergency-contraception/ • Faculty of Sexual and Reproductive Health Drug Interactions with Hormonal Contraception – May 2022 https://www.fsrh.org/standards-and-guidance/current-clinical-guidance/drug-interactions/ • Royal Pharmaceutical Society Safe and Secure Handling of Medicines December 2018 https://www.rpharms.com/recognition/setting-professional-standards/safe-and-secure-handling-of-medicines • Emergency contraception and breast-feeding - October 2023 https://www.sps.nhs.uk/articles/using-emergency-contraception-during-breastfeeding/ • Centre for Pharmacy Postgraduate Education - Contraception https://www.cppe.ac.uk/programmes/l/ehc-e-03/ • Centre for Pharmacy Postgraduate Education - Sexual Health e-learning Gateway - https://www.cppe.ac.uk/gateway/sexual • CPPE Emergency contraception gateway - https://www.cppe.ac.uk/gateway/ehc • CPPE Consultation Skills - Face to face and remote - https://www.cppe.ac.uk/gateway/cs-ftfr • CPPE Sexual health in pharmacies -https://www.cppe.ac.uk/programmes/l/sexual-e-01
---	--

5. Appendices

Appendix A	Registered Pharmacist Authorisation Sheet
Appendix B	Safeguarding Flow Chart
Appendix C	FSRH decision chart for levonorgestrel or ulipristal
Appendix D	Pharmacy service signposting

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

APPENDIX A - REGISTERED PHARMACIST AUTHORISATION SHEET**PGD HCC202402v1.0- Ulipristal Emergency Contraception****Valid from: 01/04/2024 Expiry: 31/03/2027**

Before signing this PGD, check that the document has had the necessary authorisations. Without these, this PGD is not lawfully valid.

Registered Pharmacist

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it. Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation	Signature	Date

Authorising manager

I confirm that the registered pharmacists named above are declared suitably trained and competent to work under this PGD. I give authorisation on behalf of:			
Pharmacy name: _____			
F Code: _____			
For the above named pharmacists who have signed the PGD to work under it.			
Name	Designation	Signature	Date

Score through unused rows in the list of registered health professionals to prevent additions post managerial authorisation. The patient group direction is to be read, agreed and signed by each registered pharmacist it applies to. One copy should be given to each participating Pharmacist. The original signed copy should be retained and be easily available within the Community Pharmacy.

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

APPENDIX B

If you have concerns regarding an adult who is being abused or neglected, call 0300 123 4042 (open 24 hours a day). For more information visit:

<https://www.hertfordshire.gov.uk/services/adult-social-services/report-a-concern-about-an-adult/report-a-concern-about-an-adult.aspx>

If there are concerns regarding a child being abused or neglected, follow the steps in the "Recognise, Respond and Refer" flowchart below or visit:

<https://www.hertfordshire.gov.uk/services/childrens-social-care/child-protection/report-child-protection-concern.aspx>

To make an online safeguarding referral, pharmacists need to sign-in to their account with Hertfordshire County Council which they can create from this link:

<https://eservices.hertfordshire.gov.uk/my-account> .



Children have a right to be cared for and protected and protecting them is everyone's responsibility

Safeguarding Children



Jan 2020

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024


Review date: 01/10/2026

Expiry date: 31/03/2027

APPENDIX C



**Algorithm 2: Decision-making Algorithm for Oral Emergency Contraception (EC):
Levonorgestrel EC (LNG-EC) vs Ulipristal Acetate EC (UPA-EC)**



X

Copyright ©Faculty of Sexual and Reproductive Healthcare 2017

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

Flow chart taken from:

FSRH Clinical Guideline: Emergency Contraception (March 2017, amended July 2023), available at:

<https://www.fsrh.org/documents/ceu-clinical-guidance-emergency-contraception-march-2017/>

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

APPENDIX D

Free and confidential Emergency Contraceptive services

If you are unable to provide emergency contraception to a young person, below are a range of services that you can refer to across Hertfordshire.

If making any referral on behalf of a young person, contact the services in advance to see if they are open and the appropriate staff are available to offer support.

1) Pharmacies

Some local pharmacies continue to offer free oral Emergency Contraception. To find out where they are visit in [interactive map](#).

2) Sexual Health Hertfordshire (SHH)

Sexual Health Hertfordshire offer a range of free and confidential services including pregnancy testing, emergency contraception and testing for STI's for young people living in Hertfordshire

Free Walk-in clinics for young people (21 years and under) provided by SHH: Call **0300 008 5522** or go to <https://www.sexualhealthhertfordshire.clch.nhs.uk/> for more information. Anyone over 21 can also access EHC from SHH, their GP or online from [SH:24](#) (see below)

3) On-line

Order free and confidential emergency contraception pill via [SH:24](#)

(https://sh24.org.uk/ec_now_order/age_and_postcode/new)

**If the young person is under 18 or unable to use online services, please call 0300 008 5522*

4) General practice (GP)

Patients can access emergency contraception from or via their GP

Further Online services available to Hertfordshire residents

SH:24 provides a range of free online services to residents aged 16 years or older:

- **Contraceptive pill:** order on-line via **SH:24**
- **Testing for STIs with no symptoms:** order a free test via **SH:24**

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027

- **HIV Testing:** order online from [Free Testing HIV](https://freetesting.hiv/) (<https://freetesting.hiv/>)

Young People can also ask questions about sex and relationships via the Sexual Health texting service on 07312263535 (Tuesday's and Thursdays from 1.00pm - 4.30pm). Outside of these times call 0300 008 5522. Visit <https://www.servicesforyoungpeople.org/support-for-young-people/services-for-young-people-access-point-projects/sexual-health-services/> for further information.

The Public Health Nursing Team also provide a confidential 'chat health' texting service: **0748 063 5050**. The National Sexual Health Helpline: 0300 123 7123 is open 9am-8pm, Mon-Fri, and 11am-4pm, Sat-Sun.

5) Out of hours

Advice can be obtained by calling 111. You can also obtain information from NHS:

<https://www.nhs.uk/live-well/sexual-health/where-can-i-get-sexual-health-advice-now/>

Reference Number: Ulipristal PGD HCC202402v1.0

Valid from: 01/04/2024

Review date: 01/10/2026

Expiry date: 31/03/2027